{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:15:24Z","timestamp":1788218124245,"version":"build-2803163510"},"reference-count":33,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die fokale Therapie (FT) dient der gezielten Ablation tumortragender Areale unter Erhalt\n      m\u00f6glichst gro\u00dfer Anteile gesunden Prostatagewebes. Dadurch sollen die funktionellen Vorteile\n      gegen\u00fcber radikalen Therapieformen wie der radikalen Prostatektomie oder der Strahlentherapie\n      genutzt werden, ohne die lokale Tumorkontrolle wesentlich zu beeintr\u00e4chtigen. Aktuell wird die\n      FT insbesondere f\u00fcr sorgf\u00e4ltig ausgew\u00e4hlte Patienten mit Niedrig- oder fr\u00fchem intermedi\u00e4rem\n      Risiko-Prostatakarzinom angeboten, die keine aktive \u00dcberwachung w\u00fcnschen oder f\u00fcr diese nicht\n      geeignet erscheinen. Voraussetzung f\u00fcr eine sichere Patientenselektion sind eine\n      multiparametrische Magnetresonanztomographie, gezielte sowie systematische Biopsien und eine\n      exakte Beurteilung von Tumorlokalisation, Tumorvolumen und Prostataanatomie.FT-Verfahren\n      lassen sich in thermale (z.B. Hochintensive-fokussierte Ultraschall (HI-FU) oder Kryotherapie)\n      und nicht-thermale Ablationsmethoden (vaskul\u00e4r-gezielte photodynamische Therapie (VTP) oder\n      die irreversible Elektroporation (IRE)) unterteilen. Die Verfahren unterscheiden sich\n      hinsichtlich ihres Wirkmechanismus, ihrer technischen Durchf\u00fchrung sowie ihrer Eignung f\u00fcr\n      bestimmte Tumorlokalisationen. Die Wahl des Verfahrens muss daher individuell unter\n      Ber\u00fccksichtigung der anatomischen Gegebenheiten und der physikalischen Limitationen der\n      jeweiligen Technologie erfolgen.Ziel dieses \u00dcbersichtsartikels ist es, die derzeit\n      verf\u00fcgbaren Verfahren der fokalen Therapie hinsichtlich ihrer Indikationen, technischen\n      Besonderheiten, Limitationen und ihrer Eignung f\u00fcr unterschiedliche Tumorlokalisationen\n      darzustellen. Im Fokus steht die Frage, welche Therapie f\u00fcr die entsprechende\n      Tumorlokalisation am ehesten geeignet ist. Entscheidend f\u00fcr den Therapieerfolg sind eine\n      pr\u00e4zise Diagnostik, die Ber\u00fccksichtigung der Tumorlokalisation sowie die Auswahl eines\n      geeigneten Ablationsverfahrens. Aufgrund der unterschiedlichen St\u00e4rken und Limitationen der\n      verf\u00fcgbaren Technologien sollten Zentren mehrere komplement\u00e4re Verfahren anbieten, um eine\n      individualisierte und tumorgerechte Behandlung zu erm\u00f6glichen.<\/jats:p>","DOI":"10.1055\/a-2919-7569","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:33:56Z","timestamp":1788215636000},"page":"457-464","source":"Crossref","is-referenced-by-count":0,"title":["Welche Fokale Therapie bei wem und wann?"],"prefix":"10.1055","volume":"57","author":[{"given":"Angelika","family":"Borkowetz","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin Rostock, Germany","place":["Rostock"],"department":["Klinik und Poliklinik f\u00fcr Urologie"]},{"name":"Deutsche Gesellschaft f\u00fcr Urologie eV, Germany","place":["D\u00fcsseldorf"],"department":["Arbeitskreis f\u00fcr Fokale und Mikrotherapie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-2096","authenticated-orcid":false,"given":"Martin","family":"Schostak","sequence":"additional","affiliation":[{"name":"LOGICURO GmbH, Germany","place":["Potsdam"],"department":["Urooncology"]},{"name":"Deutsche Gesellschaft f\u00fcr Urologie eV, Germany","place":["D\u00fcsseldorf"],"department":["Arbeitskreis f\u00fcr Fokale und Mikrotherapie"]},{"name":"Universit\u00e4tsklinikum Schleswig-Holstein Campus L\u00fcbeck, Germany","place":["L\u00fcbeck"],"department":["Klinik f\u00fcr Urologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41391-018-0033-1","article-title":"Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram","volume":"21","author":"RS Pompe","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1464-410X.2007.07009.x","article-title":"Does active surveillance for men with localized prostate cancer carry psychological morbidity?","volume":"100","author":"KL Burnet","year":"2007","journal-title":"BJU Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.euo.2025.01.009","article-title":"Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort","volume":"8","author":"M Baboudjian","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/JU.0000000000005060","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline Amendment (2026)","volume":"216","author":"JA Eastham","year":"2026","journal-title":"J Urol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/JU.0000000000002854","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline","volume":"208","author":"JA Eastham","year":"2022","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.16360","article-title":"The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer","volume":"134","author":"L Rodriguez-Sanchez","year":"2024","journal-title":"BJU Int"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/curroncol32010015","article-title":"Focal Therapy for Prostate Cancer: Recent Advances and Insights","volume":"32","author":"F Lasorsa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3390\/cancers18101523","article-title":"Focal Therapy for Prostate Cancer: State of the Art, Physical Principles, Potentials, and Challenges","volume":"18","author":"L Orecchia","year":"2026","journal-title":"Cancers (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00120-019-0862-0","article-title":"[Focal therapy for prostate cancer]","volume":"58","author":"M Schostak","year":"2019","journal-title":"Urologe A"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.eururo.2024.11.006","article-title":"Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial","volume":"87","author":"G Ploussard","year":"2025","journal-title":"Eur Urol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clon.2013.05.002","article-title":"Focal therapy for prostate cancer: rationale and treatment opportunities. Clin Oncol (R Coll Radiol)","volume":"25","author":"V Kasivisvanathan","year":"2013"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study","volume":"20","author":"O Rouviere","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00330-018-5584-y","article-title":"Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate","volume":"29","author":"D Bonekamp","year":"2019","journal-title":"Eur Radiol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bju.16746","article-title":"Perioperative complications of focal therapy for prostate cancer: results from the GeRmAn Nationwide inpatient Data (GRAND) study","volume":"136","author":"N Pyrgidis","year":"2025","journal-title":"BJU Int"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.euf.2022.10.006","article-title":"Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused Ultrasound: The FOXPRO Trial","volume":"9","author":"N Westhoff","year":"2023","journal-title":"Eur Urol Focus"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.juro.2017.10.033","article-title":"Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused Ultrasound","volume":"199","author":"R Ganzer","year":"2018","journal-title":"J Urol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.urolonc.2019.09.001","article-title":"Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications","volume":"38","author":"FA Schmid","year":"2020","journal-title":"Urol Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00345-020-03297-7","article-title":"Focal HIFU therapy for anterior compared to posterior prostate cancer lesions","volume":"39","author":"PM Huber","year":"2021","journal-title":"World J Urol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41391-021-00390-9","article-title":"Oncological and functional outcome after partial prostate HIFU ablation with Focal-One((R)): a prospective single-center study","volume":"24","author":"M Dellabella","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1089\/end.2021.0866","article-title":"Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review","volume":"36","author":"C Dora","year":"2022","journal-title":"J Endourol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/JU.0000000000001362","article-title":"Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer","volume":"205","author":"L Klotz","year":"2021","journal-title":"J Urol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10147-020-01847-y","article-title":"Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis","volume":"26","author":"RQ Guo","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jvir.2018.09.016","article-title":"Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk Disease","volume":"30","author":"E Walser","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prnil.2025.07.002","article-title":"Advances in focal therapy for prostate cancer: current modalities, outcomes, and future directions","volume":"14","author":"R Roldan-Testillano","year":"2026","journal-title":"Prostate Int"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41391-022-00577-8","article-title":"Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study","volume":"26","author":"PK Chiu","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"AR Azzouzi","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e13789","DOI":"10.1111\/and.13789","article-title":"A systematic review of irreversible electroporation in localised prostate cancer treatment","volume":"52","author":"A Morozov","year":"2020","journal-title":"Andrologia"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00261-024-04482-7","article-title":"Focal therapy for prostate cancer","volume":"50","author":"S Basseri","year":"2025","journal-title":"Abdom Radiol (NY)"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.rxeng.2023.04.002","article-title":"Irreversible electroporation: Beyond the limits of tumor ablation","volume":"66","author":"R Alonso-Gonzalez","year":"2024","journal-title":"Radiologia (Engl Ed)"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.prnil.2021.04.001","article-title":"A systematic review of outcomes after thermal and nonthermal partial prostate ablation","volume":"9","author":"JS Fainberg","year":"2021","journal-title":"Prostate Int"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.brachy.2013.02.002","article-title":"Focal brachytherapy for selected low-risk prostate cancers: a pilot study","volume":"12","author":"JM Cosset","year":"2013","journal-title":"Brachytherapy"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1007\/s00432-022-04491-3","article-title":"Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study","volume":"149","author":"P Hass","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12894-019-0562-5","article-title":"Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging","volume":"19","author":"C Sze","year":"2019","journal-title":"BMC Urol"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2919-7569.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:34:02Z","timestamp":1788215642000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2919-7569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":33,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2919-7569","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}